Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO MMRd-GREEN
NCT05255653Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2021
- Primary completion
- Jan 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 7
01
Overview
A Phase 3 trial of durvalumab in endometrial cancer (EC), sponsored by Leiden University Medical Center. Started Nov 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05255653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255653.